CAI vs RARE · rev $812.0M vs rev $350.0M
Caris Life Sciences, Inc. Common Stock (CAI) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
Caris Life Sciences, Inc. Common Stock (CAI) is a biotechnology company listed on NASDAQ.
Ultragenyx (RARE) is a biotechnology company listed on US.
Latest reported CAI revenue for 2025-12-31 was $812.0M. Net income was -$68.1M. Revenue was up 97.0% from 2024-12-31 to 2025-12-31. CAI currently screens at market cap $5.22B.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
CAI currently screens at market cap $5.22B. RARE currently screens at market cap $2.79B.
Not investment advice. Open the CAI and RARE stock pages for the full models.
Not investment advice.